FibroBiologics, Inc. (NASDAQ: FBLG) completed a best‑efforts public offering of 2,272,728 shares of common stock and an equal number of warrants at a price of $1.32 per share, generating approximately $3 million in gross proceeds and potentially an additional $3 million if all warrants are exercised. The offering closed on April 2, 2026, following the SEC’s effective filing of the Form S‑1 on March 31, 2026.
The company’s financial position underscores the urgency of the raise. For the year ended December 31, 2025, FibroBiologics reported a net loss of $18.6 million, up from $11.2 million in 2024, and held $4.9 million in cash and cash equivalents. A 1‑for‑20 reverse split, effective March 30, 2026, was executed to maintain Nasdaq’s minimum bid‑price requirement and to improve the stock’s marketability before the new capital infusion.
Proceeds will be used primarily for working capital and general corporate purposes, with a focus on advancing the company’s clinical pipeline. The funding is expected to support the development of CYWC628, a fibroblast‑based therapy for diabetic foot ulcers, and to facilitate the IND filing for CYPS317 in psoriasis. Given the company’s ongoing net losses and limited cash, the raise is critical for sustaining operations and clinical progress.
The announcement triggered a sharp market reaction, with the stock falling 42.11% on the day of the announcement. Investors cited the immediate dilution from the new shares and warrants, the uncertainty surrounding warrant exercise (which requires shareholder approval), and the best‑efforts nature of the offering as key drivers of the negative sentiment.
H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The transaction follows a December 2025 registered direct offering of $1.7 million, reflecting a pattern of periodic capital raises to support the company’s research and development activities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.